BPTS Biophytis SA

 

 

UNITED STATES SECURITIES 

AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER 

PURSUANT TO RULE 13a-16 OR 15d-16 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report: November 28, 2023

 

Commission File Number: 001-38974

 

BIOPHYTIS S.A. 

(Translation of registrant’s name into English)

 

 

Stanislas Veillet

Biophytis S.A. 

Sorbonne University—BC 9, Bâtiment A 4ème étage 

4 place Jussieu 

75005 Paris, France 

+33 1 44 27 23 00 

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

x  Form 20-F  ¨  Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

On November 27, 2023, Biophytis S.A. issued a press release announcing the appointment of Yann Meunier and Bernard Lévy to its Scientific Advisory Board. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

 

EXHIBIT LIST

 

Exhibit		Description
99.1		Press Release dated November 27, 2023.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BIOPHYTIS S.A.
Date: November 28, 2023	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer

 

Exhibit 99.1

 

 

Press release

 

Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board

 

Paris (France) and Cambridge (Massachusetts, USA), November 27, 2023 – 7am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related neuromuscular and respiratory diseases, today announced the appointment of Dr Yann Meunier and Professor Bernard Lévy to its Scientific Advisory Board.

 

Yann Meunier is a US-based healthcare professional, currently Professor and Director of the International Institute of Medicine and Science, Inc (IIMS), where he leads the development and implementation of innovative educational programmes and research projects in global health and related fields. He is also a consultant and health expert with HealthConnect International LLC. Over the course of his career, he has worked with leading organisations such as Stanford Hospital & Clinics, Stanford University School of Medicine, George Washington University and Université Paris VI. He has published widely in the international medical literature and, as an investigator, has led and participated in clinical trials for new treatments for HIV/AIDS, tropical and infectious diseases, and cardiovascular and respiratory diseases.

 

Bernard Lévy is Professor Emeritus of Physiology and a senior member of PARCC (Inserm U970). He headed the physiology and functional investigations department and the Inserm cardiovascular research centre at Lariboisière Hospital in Paris. After studying medicine, he focused on physiology, fluid mechanics, cardiology and vascular medicine. His work focuses on vascular biology in ageing, hypertension, diabetes and Alzheimer's disease, and he has particularly studied the functions of the renin-angiotensin system in these different diseases.

 

Stanislas Veillet, CEO of Biophytis, commented: "We are delighted to welcome two important new members to our Scientific Advisory Board, who will be able to contribute actively to the discussions and reflections on Biophytis' strategy and the development plans for our drug candidates in their various indications. In particular, Bernard Lévy will bring us his in-depth knowledge of the renin-angiotensin system, a key system for the proper functioning of muscular and cardio-respiratory functions, which we are specifically targeting with our drug candidate BIO101. For his part, Yann Meunier, the infectiologist behind the discovery of HIV, will be contributing his expertise in respiratory infections, which are still a major public health problem today. This high-level scientific support is crucial to positioning BIO101 as effectively as possible, particularly in its most advanced indications of COVID-19 and sarcopenia.”

 

* * * *

 

 

 

Press release

 

About BIOPHYTIS

 

Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. Sarconeos (BIO101), our lead drug candidate, is a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory (Covid-19) diseases. Promising clinical results were obtained in the treatment of sarcopenia in an international phase 2 study, enabling the launch of a phase 3 study in this indication (SARA project). The safety and efficacy of Sarconeos (BIO101) in the treatment of severe COVID-19 were studied in a positive international phase 2-3 clinical trial (COVA project), enabling the preparation of conditional marketing authorization (CMA) applications in Europe and Emergency Use Authorization (EUA) applications in the United States. A pediatric formulation of Sarconeos (BIO101) is currently being developed for the treatment of Duchenne Muscular Dystrophy (DMD, MYODA project). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information, visit www.biophytis.com.

 

Disclaimer

 

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as «outlook, "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward- looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company’s 2022 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

 

Biophytis contacts

 

Investor relations

 

Nicolas Fellmann, CFO 

Investors@biophytis.com

 

Media

 

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27 

Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50

 

 

---